Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition

This study has been completed.
Sponsor:
Information provided by:
Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier:
NCT01064232
First received: February 4, 2010
Last updated: NA
Last verified: February 2010
History: No changes posted

February 4, 2010
February 4, 2010
October 2006
October 2006   (final data collection date for primary outcome measure)
Bio-equivalence study of Dr Reddys Laboratories Risperidone Tablets 1 mg [ Time Frame: 3-4 months ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition
A Relative Bioavailability Study of Two Risperidone 1 mg Tablet Formulations Under Fasting Conditions

A Single-dose, Randomized, two-Period, Cross over Study

Randomized, single-dose, two-way, crossover study was conducted to compare the relative bioavailability of two formulations of 1 mg risperidone tablets under fasting conditions.

The test formulation was Dr. Reddy's Laboratories Limited's Risperidone Tablets, 1 mg, and the reference formulation was Risperdal® (risperidone) tablets, 1 mg (Janssen Pharmaceutica Products, L.P.).

The study was conducted with 30 healthy adults. In each study period, a single 1 mg dose was administered to all subjects following an overnight fast.The subjects received the test product in one study period and the reference product in the other period; the order of administration was according to the dosing randomization schedule. There was a 7-day interval between treatments.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy
Drug: Risperidone
Risperidone Tablets 1 mg
Other Name: Risperdal® Tablets, 1 mg
  • Experimental: Risperidone
    Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
    Intervention: Drug: Risperidone
  • Active Comparator: Risperdal
    Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
    Intervention: Drug: Risperidone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
October 2006
October 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males and females, 18 - 55 years of age.
  2. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable method of contraception (e.g. condom with spermicide, IUD, hormonal contraceptives) for at least 30 days prior to dosing and during the duration of the study.
  3. A body mass index (BMI) of 18-30 kg/m² inclusive as calculated according to Novum Standard Operating Procedures.
  4. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
  5. Signed and dated informed consent form, which meets all criteria of current FDA regulations.

Exclusion Criteria:

  1. If female, pregnant, lactating or likely to become pregnant during the study.
  2. History of allergy or sensitivity to risperidone, or similar drugs, or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  3. Significant history or current evidence of chronic infectious disease, system disorder or organ dysfunction.
  4. Presence of gastrointestinal disease or history of malabsorption within the last year.
  5. History of psychiatric disorders occurring within the last two years that required hospitalization or medication.
  6. Presence of a medical condition requiring regular treatment with prescription drugs.
  7. Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to initial dosing.
  8. Receipt of any drug as part of a research study within 30 days prior to dosing.
  9. Drug or alcohol addiction requiring treatment in the past 12 months.
  10. Donation or significant loss of whole blood (480 ml or more) within 30 days or plasma within 14 days prior to dosing.
  11. Positive test results for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
  12. Positive test results for drugs of abuse at screening.
  13. Positive serum pregnancy test.
  14. Subjects who smoke more than 10 cigarettes/day or equivalent tobacco use.
  15. Subjects who have been on a special diet during the 28 days prior to dosing
  16. Subjects who consume on average more than 3 units of alcohol/day.
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01064232
10640601
No
Senior Director - Research & Development, Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited
Not Provided
Principal Investigator: Soran Hong, MD Novum Pharmaceutical Research Services, 3320 Walnut Bend Lane, Honston, Texas 77042-4712, USA
Dr. Reddy's Laboratories Limited
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP